A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Save

Date Added
April 21st, 2017
PRO Number
Pro00062582
Researcher
Ria Gripaldo
Keywords
Immune System, Inflammation, Lung, Pulmonary, Shortness of Breath
Summary

This study is being done to see how well the study drug, called nintedanib, may help your lung disease and to compare safety and effects of nintedanib with a placebo in participants with Progressive Firbrosing Interstitial Lung Disease (PF-ILD).

Institution
Palmetto
Recruitment Contact
Ria Gripaldo
803-434-3800
ClinicalTrialSurvey@PalmettoHealth.org

Change_preferences

-- OR --

Create_login